Madrigal Pharmaceuticals poised for market dominance with Rezdiffra’s first full quarter success and growing MASH market potential Read more
Obesity drug tirzepatide approval in China strengthens market position amid GLP-1 agonist competition: GlobalData Read more
Rubicon Research files for IPO with SEBI, Targets ₹10,850 Million to drive growth and innovation Read more
Viking Therapeutics’ obesity drug could become direct competitor to Eli Lilly’s tirzepatide: GlobalData Read more
Vector Consulting Group reveals strategies for pharma firms to boost agility and cost efficiency in the US market Read more